Safety and Efficacy of the HighLife Transcatherter Mitral Valve Replacement System in Patients With Moderate-severe or Severe Mitral Regurgitation in China

NARecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

July 6, 2022

Primary Completion Date

July 6, 2025

Study Completion Date

July 6, 2029

Conditions
Mitral Regurgitation
Interventions
DEVICE

the HighLife Trans-Septal Transcatheter Mitral Valve Replacement System

The HighLife TMVR system is composed of a Transcatheter Mitral Valve (TMV), a subannular implant (SAI), and their delivery systems and accessories. The TMV is a 28mm mitral bioprosthesis made of a self-expanding Nitinol frame covered with polyester graft and supporting bovine pericardium leaflets. The bioprosthesis is used in conjunction with the Sub-Annular Implant (SAI), comprising a ring (made of polycarbonate urethane (PCU), nitinol, gold markers and polyester (Dacron) to be placed around the mitral valve apparatus to stabilize the position of the mitral valve implant.

Trial Locations (1)

215025

RECRUITING

Peiga Medical Technology (Suzhou) Co., Suzhou

All Listed Sponsors
collaborator

West China Hospital

OTHER

collaborator

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

collaborator

The Second Affiliated Hospital of Harbin Medical University

OTHER

lead

Peijia Medical Technology (Suzhou) Co., Ltd.

INDUSTRY